Trastuzumab And Hyaluronidase-Oysk
Breast Cancer Female
Adrienne G. WaksPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Breast Cancer Female cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darolutamide Vandana Abramson | Phase 2 | BBB |
Ramosetron Pusan National University Hospital | Phase 4 | BB |
ROPIVACAINE Columbia University | Phase 4 | BB |
L-Bupivacaine Osijek University Hospital | Phase 4 | BB |
Meperidine Osijek University Hospital | Phase 4 | BB |
View all 36 →
Same molecule, other indications
Trastuzumab And Hyaluronidase-Oysk is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →